Literature DB >> 26104952

Regenerative medicine in otorhinolaryngology.

J C R Wormald1, J M Fishman2, S Juniat3, N Tolley1, M A Birchall3.   

Abstract

BACKGROUND: Tissue engineering using biocompatible scaffolds, with or without cells, can permit surgeons to restore structure and function following tissue resection or in cases of congenital abnormality. Tracheal regeneration has emerged as a spearhead application of these technologies, whilst regenerative therapies are now being developed to treat most other diseases within otolaryngology. METHODS AND
RESULTS: A systematic review of the literature was performed using Ovid Medline and Ovid Embase, from database inception to 15 November 2014. A total of 561 papers matched the search criteria, with 76 fulfilling inclusion criteria. Articles were predominantly pre-clinical animal studies, reflecting the current status of research in this field. Several key human research articles were identified and discussed.
CONCLUSION: The main issues facing research in regenerative surgery are translation of animal model work into human models, increasing stem cell availability so it can be used to further research, and development of better facilities to enable implementation of these advances.

Entities:  

Keywords:  Audiology; Head And Neck Cancer; Laryngology; Otology; Otorhinolaryngology; Reconstructive Surgical Procedures; Regenerative Medicine; Rhinology; Stem Cells; Tissue Engineering

Mesh:

Substances:

Year:  2015        PMID: 26104952     DOI: 10.1017/S0022215115001577

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  1 in total

1.  Comparative Morphological Characteristics of the Results of Implantation of Decellularized and Recellularized Porcine Skin Scaffolds.

Authors:  A S Sotnichenko; I V Gilevich; K I Melkonyan; Y A Yutskevich; T V Rusinova; A V Karakulev; S B Bogdanov; V A Aladina; Yu A Belich; S E Gumenyuk; D I Ushmarov; I M Bykov; A N Redko; V A Porhanov; S N Alekseenko
Journal:  Bull Exp Biol Med       Date:  2021-01-16       Impact factor: 0.804

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.